Summary of bi-shRNAfurin/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver

Oncology (Switzerland)

Volumn 87, Issue 1, 2014, Pages 21-29

  Nemunaitis, John ^a,b,c,e   Barve, Minal ^a,e   Orr, Douglas ^d   Kuhn, Joseph ^f   Magee, Mitchell ^g   Lamont, Jeffrey ^d   Bedell, Cynthia ^a   Wallraven, Gladice ^b   Pappen, Beena O ^b   Roth, Alyssa ^a   Horvath, Staci ^a   Nemunaitis, Derek ^a   Kumar, Padmasini ^b   Maples, Phillip B ^b   Senzer, Neil ^a,b,c,e  

^a Mary Crowley Cancer Research Centers   (United States)

^b Texas Oncology   (United States)

^c Medical City Dallas Hospital   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e Texas Oncology   (United States)

^f WLS Surgical Associ PA   (United States)

^g Cardiovascular Specialty Associ of North Texas PA   (United States)

Author keywords

FANG ; Hepatocellular carcinoma; Immunotherapy; Phase I study; RNA interference

Indexed keywords

CANCER VACCINE; DNA; FANG; FURIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR BIFUNCTIONAL SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SHORT HAIRPIN RNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; DRUG SAFETY; DRUG TREATMENT FAILURE; EX VIVO STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LONG TERM CARE; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; RNA VECTOR; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; CANCER PATIENT; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GENE SILENCING; IMMUNOTHERAPY; MIDDLE AGED; TRANSGENE;

ADULT; AGED; CANCER VACCINES; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, INTRADERMAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VACCINATION;

EID: 84902890484     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000360993     Document Type: Article

References (63)

1. Kumar V, Abbas A, Fausto N; in Kumar V, Fausto N, Abbas A, Robbins SL, Cotran RS (eds): Robbins and Cotran Pathologic Basis of Disease (ed 7). Philadelphia, Elsevier Saunders, 2005, pp 914-917.
2. Keating GM, Santoro A: Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
4. Villanueva A, Llovet JM: Second-line therapies in hepatocellular carcinoma: Emergence of resistance to sorafenib. Clin Cancer Res 2012; 18: 1824-1826.
5. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92.
6. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al: Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18: 3686-3696.
7. El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-1763.
8. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al: Treatment strategy for small hepatocellular carcinoma: Comparison of long-Term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001; 34(4 Pt 1):707-713.
9. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al: A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328.
10. Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, et al: Treatment of hepatocellular carcinoma: Present and future. Exp Rev Anticancer Ther 2013; 13: 469-479.
11. Ni JY, Xu LF, Sun HL, Zhou JX, Chen YT, Luo JH: Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: A meta-Analysis of 21,494 patients. J Cancer Res Clin Oncol 2013; 139: 2021-2033.
12. Giunchedi P, Maestri M, Gavini E, Dionigi P, Rassu G: Transarterial chemoembolization of hepatocellular carcinoma-Agents and drugs: An overview. Part 2. Expert Opin Drug Deliv 2013; 10: 799-810.
13. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364.
14. Takayama T: Surgical treatment for hepatocellular carcinoma. JJCO 2011; 41: 447-454.
15. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009; 10: 25-34.
16. Butterfield LH: Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 2004; 127(5 suppl 1):S232-S241.
17. Nemunaitis J: Multifunctional vaccines in cancer: The 'triad' approach. Expert Rev Vaccines 2011; 10: 713-715.
18. Zhuang L, Zeng X, Yang Z, Meng Z: Effect and safety of interferon for hepatocellular carcinoma: A systematic review and meta-Analysis. PLoS One 2013; 8:e61361.
19. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al: Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19: 329-336.
20. Jennerex Biotherapeutics: Jennerex and transgene present positive clinical data from phase 2 trial of JX594/ TG6006 in sorafenib-refractory liver cancer patients, 2012. http://www.transgene.fr/index.php?option=com-press- release&task=download&id=214&l=en (accessed October 2013).
21. Sawada Y, Ofuji K, Sakai M, Nakatsura T: Immunotherapy for hepatocellular carcinoma: Current status and future perspectives, 2013, DOI: 10.5772/54594.
22. Abe M, Thomson A: Antigen processing and presentation in the liver; in Gershwin ME, Vierling JM, Manns MP (eds): Liver Immunology Principles and Practice. New York, Human Press Inc., 2007, pp 49-59.
23. Knolle PA, Gerken G: Local control of the immune response in the liver. Immunol Rev 2000; 174: 21-34.
24. Crispe IN: Hepatic T cells and liver tolerance. Nat Rev Immunol 2003; 3: 51-62.
25. Satthaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, et al: Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 2004; 53: 510-518.
26. Ormandy LA, Farber A, Cantz T, Petrykowska S, Wedemeyer H, Horning M, et al: Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12: 3275-3282.
27. Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, et al: Phase I trial of 'bi-shRNAi(furin)/GMCSF DNA/ autologous tumor cell' vaccine (FANG) in advanced cancer. Mol Ther 2012; 20: 679-686.
28. Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, Pappen BO, et al: Enhanced target gene knockdown by a bifunctional shRNA: A novel approach of RNA interference. Cancer Gene Ther 2010; 17: 780-791.
29. Senzer N, Barve M, Nemunaitis J, Kuhn J, Melnyk A, Beitsch P, et al: Long-Term follow-up: Phase I trial of 'bi-shRNA furin/GMCSF DNA/autologous tumor cell' immunotherapy (FANG TM ) in advanced cancer. J Vaccines Vaccin 2013; 4: 209.
30. Maples PB, Kumar P, Yu Y, Wang Z, Jay CM, Pappen BO, et al: FANG vaccine: Autologous tumor vaccine genetically modified to express GM-CSF and block production of furin. BPJ 2010; 8: 4-14.
31. Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C, et al: Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 2011; 17: 183-192.
32. Yoong KF, Adams DH: Phenotypic and functional analyses of fresh and recombinant interleukin-2 cultured tumour-infiltrating lymphocytes derived from malignant human liver tumours. Biochem Soc Trans 1997; 25: 271S.
33. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M: Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998; 27: 407-414.
34. Breous E, Thimme R: Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 2011; 54: 830-834.
35. Greten TF, Manns MP, Korangy F: Immunotherapy of hepatocellular carcinoma. J Hepatol 2006; 45: 868-878.
36. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000; 356: 802-807.
37. Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, et al: Phase II randomized trial of autologous formalinfixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 2004; 10: 1574-1579.
38. Peng BG, Liang LJ, He Q, Kuang M, Lia JM, Lu MD, et al: Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol 2005; 11: 700-704.
39. Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, et al: Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999; 59: 3064-3067.
40. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, et al: T-cell responses to HLA-A 0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 2003; 9(16 Pt 1):5902-5908.
41. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, et al: A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006; 12: 2817-2825.
42. Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T: Peptide vaccines for hepatocellular carcinoma. Hum Vaccin Immunother 2013; 9: 210-212.
43. Nakatsura T: Annual Report 2012: Division of Cancer Immunotherapy; 2012. http://www.ncc.go.jp/en/publication/2012/ncce/ncce31-02.html.
44. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, et al: Prospective randomized controlled study of interferonalpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004; 100: 376-382.
45. Lygidakis NJ, Kosmidis P, Ziras N, Parissis J, Kyparidou E: Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: A new alternative for an old problem. J Interferon Cytokine Res 1995; 15: 467-472.
46. Reinisch W, Holub M, Katz A, Herneth A, Lichtenberger C, Schoniger-Hekele M, et al: Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma. J Immunother 2002; 25: 489-499.
47. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, et al: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: A randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-465.
48. Bissell DM, Wang SS, Jarnagin WR, Roll FJ: Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 1995; 96: 447-455.
49. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, et al: Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 2007; 132: 1937-1946.
50. Gabrilovich D: Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4: 941-952.
51. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103.
52. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, et al: Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92: 4778-4791.
53. Yang AS, Lattime EC: Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003; 63: 2150-2157.
54. Kurokohchi K, Carrington M, Mann DL, Simonis TB, Alexander-Miller MA, Feinstone SM, et al: Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 1996; 23: 1181-1188.
55. Fujiwara K, Higashi T, Nouso K, Nakatsukasa H, Kobayashi Y, Uemura M, et al: Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19: 1121-1127.
56. Huang J, Cai MY, Wei DP: HLA class I expression in primary hepatocellular carcinoma. World J Gastroenterol 2002; 8: 654-657.
57. Wu K, Kryczek I, Chen L, Zou W, Welling TH: Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009; 69: 8067-8075.
58. Chen C, Zhang C, Zhuang G, Luo H, Su J, Yin P, et al: Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development. Cancer Invest 2008; 26: 965-974.
59. Shen HW, Gao SL, Wu YL, Peng SY: Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol 2005; 11: 5926-5930.
60. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 2457-2464.
61. Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, Watanabe H, et al: Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006; 45: 254-262.
62. Unitt E, Rushbrook SM, Marshall A, Davies S, Gibbs P, Morris LS, et al: Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells. Hepatology 2005; 41: 722-730.
63. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, et al: Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 2004; 10: 7260-7269.